**Hydrocortisone**

**Indication** | Lymphoid leukaemia, not elsewhere classified  
**INN** | Hydrocortisone  
**Medicine type** | Chemical agent  
**List type** | Complementary (EML) (EMLc)  
**Formulations** | Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)  
**EML status history** | First added in 2015 (TRS 994)  
**Sex** | All  
**Age** | Also recommended for children  
**Therapeutic alternatives** | The recommendation is for this specific medicine  
**Patent information** | Patents have expired in most jurisdictions  
**Tags** | Cancer  

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for hydrocortisone on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee’s 2015 consideration of treatment protocols for ALL is attached.